Skip to content

Study · Not a test of the peptide alone · 2015

9 results

PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury.

Ruozi B, Belletti D, Sharma HS, Sharma A, Muresanu DF, Mössler H, Forni F, Vandelli MA, Tosi G

Molecular neurobiology1 Oct 2015Cited by 45 (Europe PMC)

PMID26108180 (opens in a new tab)DOI10.1007/s12035-015-9235-x (opens in a new tab)PepBankPUB-26108180
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, Cerebrolysin-loaded PLGA nanoparticles reduced brain pathology.

    In plain wordsIn rats with traumatic brain injury, Cerebrolysin-loaded nanoparticles reduced brain pathology.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBrain pathology after traumatic brain injury
    Study

    ratn: not reported in source

    Traumatic brain injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    These PLGA NPs loaded with cerebrolysin were able to reduce brain pathology following traumatic brain injury.
    1 context sentence
    Summary · context
    This paper investigates the potential of polylactic-co-glycolide (PLGA) nanoparticles (NPs) as sustained release systems for iv administration of cerebrolysin in normal and brain injured rats.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In laboratory preparation tests, Cerebrolysin-loaded C-NPs4 nanoparticles had drug loading of 24 ± 1 mg/100 mg of nanoparticles.

    In plain wordsIn lab tests, Cerebrolysin-loaded nanoparticles had the reported drug loading.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableDrug loading
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    Drug loading
    24 mg/100 mg of NPs
    C-NPs4

    Source sentences

    Summary
    (C-NPs4) displayed an adequate loading of drug (24 ± 1 mg/100 mg of NPs)

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In laboratory tests, Cerebrolysin-loaded C-NPs4 nanoparticles had a zeta potential of -13 mV.

    In plain wordsIn lab tests, Cerebrolysin-loaded nanoparticles had a zeta potential of -13 mV.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableZeta potential
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    Zeta potential
    −13 mV
    C-NPs4

    Source sentences

    Summary
    (C-NPs4) displayed an adequate loading of drug (24 ± 1 mg/100 mg of NPs), zeta potential value (-13 mV)

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  4. 04LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In laboratory tests, Cerebrolysin-loaded nanoparticles had average diameters ranging from 250 to 330 nm.

    In plain wordsIn lab tests, Cerebrolysin-loaded nanoparticles had average diameters ranging from 250 to 330 nm.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAverage diameter
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    Average diameters
    250 to 330 nm
    C-NPs4

    Source sentences

    Summary
    and average diameters (ranged from 250 to 330 nm) suitable to iv administration.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  5. 05LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In SEM images, Cerebrolysin appeared molecularly dispersed in matricial systems and partially adhered to nanoparticle surfaces.

    In plain wordsIn lab tests, Cerebrolysin appeared dispersed within nanoparticles and partly attached to their surfaces.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableDrug distribution in nanoparticles
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    SEM images suggested that cerebrolysin was molecularly dispersed into matricial systems and partially adhered to the NP surface.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  6. 06LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In laboratory tests, Cerebrolysin-loaded nanoparticles showed an initial burst followed by sustained release over 24 h.

    In plain wordsIn lab tests, Cerebrolysin-loaded nanoparticles showed an initial burst followed by sustained release over 24 h.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableRelease profile
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    A biphasic release with an initial burst effect followed by sustained release over 24 h was observed.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  7. 07LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In serum incubation tests, incubation time and serum concentration significantly affected the size of Cerebrolysin-loaded nanoparticles.

    In plain wordsIn lab tests, incubation time and serum concentration changed the size of Cerebrolysin-loaded nanoparticles.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNanoparticle size in serum
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    However, the size, the polydispersivity, and the surface properties of sample were significantly affected by the incubation time and the serum concentration.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  8. 08LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In serum incubation tests, incubation time and serum concentration significantly affected the polydispersivity of Cerebrolysin-loaded nanoparticles.

    In plain wordsIn lab tests, incubation time and serum concentration changed the polydispersivity of Cerebrolysin-loaded nanoparticles.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNanoparticle polydispersivity in serum
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    However, the size, the polydispersivity, and the surface properties of sample were significantly affected by the incubation time and the serum concentration.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  9. 09LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In serum incubation tests, incubation time and serum concentration significantly affected surface properties of Cerebrolysin-loaded nanoparticles.

    In plain wordsIn lab tests, incubation time and serum concentration changed surface properties of Cerebrolysin-loaded nanoparticles.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNanoparticle surface properties in serum
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    However, the size, the polydispersivity, and the surface properties of sample were significantly affected by the incubation time and the serum concentration.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.